López GVR, Rossello VE, Andrade MN, Blanzari MJ, Bringas AL, Nocito MJ, Maldonado S, Gómez ZMS, del Valle Papa MB

Language: Spanish
References: 24
Page: 109-114
PDF size: 259.71 Kb.

ABSTRACT

Introduction: Hidradenitis suppurativa (HS) is a chronic autoinflammatory disease, whose physiopathogenesis may be related to the metabolic syndrome (MS). Objective: To compare the frequency of metabolic syndrome in patients with hidradenitis suppurativa in relation to a control group. Material and methods: Observational, retrospective and analytical study with non-probabilistic sample design. We analyzed cases of patients with hidradenitis suppurativa and randomly selected controls, matched by age and sex. The following variables were studied: Hurley stage, quality of life, sex, age, weight, height, body mass index (BMI) and the components of metabolic syndrome according to the Adult Treatment Panel III. Results: 22 cases and 44 controls were studied. Patients with hidradenitis suppurativa were mostly women (72.7%), between 31 and 40 years (31.8%), Hurley stage I (54.6%) with mild impairment of quality of life (54.6%), obese (63.7%), with increased abdominal perimeter (86.4%) and lower HDL than suggested by ATP III (59.1%). Two patients (9.1%) had arterial hypertension and five (22.7%) met the criteria for metabolic syndrome. The presence of obesity was more frequent amongnst cases (OR 2.82 IC 1.50-5.27 p = 0.006), with greater frequency of increased abdominal circumference (OR 5.78 IC 1.49-22.39 p = 0.007) and decreased HDL (p = 0.06 OR 3.10 IC 1.07-8.94). Conclusion: In the studied population it was not possible to prove a higher prevalence of metabolic syndrome, but a direct relationship was observed with obesity (BMI and increased abdominal perimeter).

REFERENCES

1. Miller IM, Ellervik C, Randskov-Vinding G, Zarchi K, Ibler KS, Knudsen KM et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol. 2014; 150: 1273-1280.

2. Dessinioti C, Katsambas A, Antoniou C. Hidradenitis suppurrativa (acne inversa) as a systemic disease. Clin Dermatol. 2014; 32: 397-408.

3. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009; 60: 539-561.

4. Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008; 59: 596-601.

5. Pascoe VL, Kimball AB. Hidradenitis suppurativa current progress and future questions. JAMA Dermatol. 2014; 150: 1263-1264.

6. Frew JW, Vekic DA, Woods J, Cains GD. Phenotypic heterogeneity implies heterogeneous pathogenic pathways in hidradenitis suppurativa. Exp Dermatol. 2015; 24: 338-339.

7. Miller IM. Co-morbidities in inflammatory dermatological diseases. Psoriasis, hidradenitis suppurativa, and cardiovascular risk factors. Dan Med J. 2015; 62 (9): B5143.

8. Wortsman X, Jemec GB. Real-time compound imaging ultrasound of hidradenitis suppurativa. Dermatol Surg. 2007; 33 (11): 1340-1342.

9. Martorell A, García-Martínez FJ, Jiménez-Gallo D, Pascual JC, Pereyra-Rodriguez J, Salgado L et al. Actualización en hidradenitis supurativa(I): epidemiología, aspectos clínicos y definición de severidad de la enfermedad. Actas Dermosifiliogr. 2015; 106: 703-715.

10. Scheinfeld N. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis. Dermatol Online J. 2013; 19: 18558.

11. Kohorst JJ, Kimball AB, Davis MDP. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015; 73: S27-S35.

12. Gold DA, Reeder VJ, Mahan MG, Hamzavi IH. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2014; 70: 699-703.

13. Lavieri A, Sehtman A, Greco C, Acevedo A. Otra mirada hacia la hidradenitis supurativa: cuando las terapias de tercera línea se convierten en la primera indicación. Dermatol Argent. 2016; 22: 96-108.

14. U.S. Department of Health and Human Services. National Cholesterol Education Program: ATP III Guidelines At-A-Glance. Quick Desk Reference. NIH Publication 2001: 01-3305.

15. Shalom G, Freud T, Harman-Boehm I, Polishchuk I, Cohen AD. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol. 2015; 173: 464-470.

16. Veysey EC. Hidradenitis suppurativa and the metabolic syndrome. Br J Dermatol. 2015; 173: 325-326.

17. Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012; 7: e31810.

18. Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The dermatology life quality index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008; 159: 997-1035.

19. Finlay AY, Khan GK. Cuestionario sobre la calidad de vida-Dermatología. Disponible en: http://www.solapso.org/archivos/evaluacion/DLQI-es.pdf.

20. Vilanova I, Hernández JL, Mata C, Durán C, García-Unzueta MT, Portilla V et al. Insulin resistance in hidradenitis suppurativa: a case-control study. J Eur Acad Dermatol Venereol. 2018; 32: 820-824.

21. Vossen ARJV, van der Zee HH, Onderdijk AJ, Boer J, Prens EP. Hidradenitis suppurativa is not associated with the metabolic syndrome based on body type: A cross-sectional study. J Dermatol. 2017; 44: 154-159.

22. Pascual JC, González I, Corona D, Hispán P, Ramos JM, Sánchez-Paya J et al. Assessment of subclinical atherosclerosis in Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol. 2016; 31: 1229-1238.

23. Dauden E, Lazaro P, Aguilar MD, Blasco AJ, Suarez C, Marin I et al. Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2018; 32: 129-144.

24. Ergun T. Hidradenitis suppurativa and the metabolic syndrome. Clin Dermatol. 2018; 36: 41-47.